Page last updated: 2024-08-25

rosiglitazone and Parkinsonian Disorders

rosiglitazone has been researched along with Parkinsonian Disorders in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A1
Carta, AR; Casu, MA; Diana, A; Lecca, D; Mulas, G; Nevin, DK; Rossi, D; Sacchetti, G1
Brenton, J; Cordeiro, MF; Davis, BM; De Groef, L; Guo, L; Malaguarnera, G; Nizari, S; Normando, EM; Pahlitzsch, M; Ravindran, N; Somavarapu, S; Turner, LA1
Carboni, E; Carta, AR; Frau, L; Pisanu, A; Spiga, S; Wardas, J1
Koh, HC; Lee, EY; Lee, JE; Park, JH; Shin, IC1

Other Studies

5 other study(ies) available for rosiglitazone and Parkinsonian Disorders

ArticleYear
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Neurobiology of disease, 2015, Volume: 74

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones

2015
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
    Neuroscience, 2015, 08-27, Volume: 302

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Encephalitis; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; NF-kappa B; Parkinsonian Disorders; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Thiobarbiturates; Tyrosine 3-Monooxygenase

2015
The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
    Acta neuropathologica communications, 2016, 08-18, Volume: 4, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Cell Survival; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Follow-Up Studies; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rats; Retina; Rosiglitazone; Rotenone; Superior Sagittal Sinus; Thiazolidinediones; Tomography, Optical Coherence

2016
Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Neuroscience, 2011, Oct-27, Volume: 194

    Topics: Animals; Disease Models, Animal; Disease Progression; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha

2011
Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Toxicology letters, 2012, Sep-18, Volume: 213, Issue:3

    Topics: Animals; Basal Ganglia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Injections, Intraperitoneal; Male; Microfilament Proteins; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Substantia Nigra; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase

2012